At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 500 enrolled
Drug / intervention
CM310 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Patients With Moderate-to-severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating CM310 and Placebo for Atopic Dermatitis. Completed, enrolled 500 participants across 1 site.
Detailed Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in patients with moderate-to-severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionOct 2023
Study CompletionDec 2023
TodayJul 2026
First PostedMar 4, 2022
Enrollment StartApr 22, 2022
Primary CompletionOct 31, 2023
Study CompletionDec 25, 2023
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 4.3 years ago
Interventions
CM310drug
IL-4Rα monoclonal antibody
Placeboother
Placebo